|
Characteristics
|
Study group (n = 111)
|
Validation group (n = 41)
|
P
value
|
|---|
|
Men
|
86 (77.5%)
|
31 (75.6%)
|
0.83
|
|
Women
|
25 (22.5%)
|
10 (24.4%)
|
0.83
|
|
Age (years)
|
58.8 ± 10.4
|
61 ± 10.6
|
0.277
|
|
BMI (kg/m2)
|
28.1 ± 4.7
|
28.9 ± 5.1
|
0.517
|
|
Hypertension
|
62 (55.9%)
|
28 (71.8%)
|
0.09
|
|
Diabetes
|
26 (23.4%)
|
6 (15.4%)
|
0.367
|
|
Previous MI
|
8 (7.2%)
|
3 (7.7%)
|
1
|
|
Smoking
|
54 (48.6%)
|
20 (51.3%)
|
0.853
|
|
Hypercholesterolemia
|
60 (54.1%)
|
34 (87.2%)
|
<0.001
|
|
AMI
|
54 (51.4%)
|
17 (43.6%)
|
0.456
|
|
Previous revascularization
|
3 (2.7%)
|
2 (5.1%)
|
0.605
|
|
Non-coronary atherosclerosis
|
6 (5.4%)
|
3 (7.7%)
|
0.697
|
|
NT-proBNP (pg/mL)
|
1,641.4 ± 3,675.3
|
2,913.3 ± 6,975.7
|
0.559
|
|
LVEF (%)
|
49.3 ± 8.6
|
42.1 ± 8.3
|
<0.001
|
|
Medicationsa
|
|
Aspirin
|
105 (100%)
|
39 (100%)
|
NA
|
|
Clopidogrel
|
104 (99%)
|
39 (100%)
|
1
|
|
Beta blockers
|
104 (99%)
|
38 (97.4%)
|
0.47
|
|
ACE inhibitors
|
100 (95.2%)
|
39 (100%)
|
0.324
|
|
Statins
|
103 (98.1%)
|
39 (100%)
|
1
|
|
Diuretics
|
21 (20%)
|
14 (35.9%)
|
0.079
|
-
aData were only available for n = 105 patients from the study group and n = 39 from validation group; these numbers were used to calculate percentages.
- Data at admission.
- Data are presented as mean value ± standard deviation or number or percentage of patients. P value <0.05 was considered significant.
- ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.
